IV 
118TH CONGRESS 
2D SESSION 
H. RES. 1286 
Supporting the role of the United States in helping save the lives of children 
and protecting the health of people in low-income countries with vaccines 
and immunization through Gavi, the Vaccine Alliance (‘‘Gavi’’). 
IN THE HOUSE OF REPRESENTATIVES 
JUNE 11, 2024 
Mr. KEAN of New Jersey (for himself, Mr. AMO, Ms. SALAZAR, and Ms. JA-
COBS) submitted the following resolution; which was referred to the Com-
mittee on Foreign Affairs 
RESOLUTION 
Supporting the role of the United States in helping save 
the lives of children and protecting the health of people 
in low-income countries with vaccines and immunization 
through Gavi, the Vaccine Alliance (‘‘Gavi’’). 
Whereas, prior to 2000, the distribution of and the resources 
for vaccines for children in the developing world were de-
clining, immunization rates were stagnant or decreasing, 
and nearly 10,000,000 children died each year before 
reaching their 5th birthday; 
Whereas, prior to 2000, it was common for new lifesaving 
vaccines to take up to 15 years to be introduced in the 
world’s most impoverished countries; 
VerDate Sep 11 2014 
01:48 Jun 12, 2024
Jkt 049200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6300
E:\BILLS\HR1286.IH
HR1286
kjohnson on DSK7ZCZBW3PROD with $$_JOB
•HRES 1286 IH 
Whereas access to routine immunization and vaccines pro-
tects children from deadly but preventable diseases and 
contributes to national economic growth and poverty re-
duction by ensuring people live longer, healthier, and 
more productive lives; 
Whereas, in 2000, the United States, the United Nations 
Children’s Fund (UNICEF), the World Health Organiza-
tion (WHO), the World Bank, government donors, lower- 
income country governments, foundations (including the 
Bill & Melinda Gates Foundation), the private sector (in-
cluding the vaccine industry), faith-based organizations, 
civil society, and other partners joined forces to create a 
public-private partnership now known as Gavi, the Vac-
cine Alliance, in order to expand access to new and 
underused vaccines and support the introduction and 
scaleup of these vaccines into routine immunization sys-
tems in the world’s most impoverished countries; 
Whereas, from 2000 through 2022, with support from the 
United States, and other donors and partners, Gavi has 
supported country-led vaccine initiatives in 78 countries 
to support the immunization of more than 1,000,000,000 
additional children and averted an estimated 17,300,000 
deaths in the world’s most impoverished countries; 
Whereas Gavi has been a major contributor in reducing the 
number of childhood deaths in lower-income countries 
due to vaccine-preventable disease by 70 percent since 
2000; 
Whereas country ownership and sustainability are at the core 
of the Gavi model, which requires Gavi-eligible countries 
to contribute to a portion of vaccine costs and directly in-
vest in immunizing children, and Gavi-supported coun-
VerDate Sep 11 2014 
01:48 Jun 12, 2024
Jkt 049200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6300
E:\BILLS\HR1286.IH
HR1286
kjohnson on DSK7ZCZBW3PROD with $$_JOB
•HRES 1286 IH 
tries contributed more than $1,500,000,000 to immuniza-
tion campaigns between 2008 and 2022; 
Whereas 78 low-income countries currently provide co-financ-
ing for new and underused vaccines supported by Gavi, 
more than 19 countries have transitioned from Gavi sup-
port by the end of 2022, and an additional 10 countries 
may transition by 2040, moving toward fully funding 
their immunization programs; 
Whereas Gavi has transformed the market for vaccines by 
matching pooled demand from low-income countries with 
secure, predictable financing to make vaccines more af-
fordable and supply more reliable, reducing the price of 
the most common vaccines by 24 percent from 2015 to 
2020 and increasing the number of global vaccine manu-
facturers selling pre-qualified Gavi-supported vaccines to 
the world’s most impoverished countries from 5 in 2001 
to 18 in 2018; 
Whereas Gavi estimates that its market shaping efforts will 
result in savings of over $900,000,000 from 2021 to 
2025 and may encourage research and development of 
new vaccines; 
Whereas Gavi is poised to provide the most comprehensive 
package of support in the 2021 to 2025 period by financ-
ing and delivering 18 vaccines to the world’s most impov-
erished countries; 
Whereas Gavi, the African Union, and the Africa Centers for 
Disease Control (Africa CDC) have jointly established the 
African Vaccine Manufacturing Accelerator (AVMA) to 
provide innovative financing to expand sustainably vac-
cine manufacturing capacity in Africa and improve the 
region’s resilience in the face of pandemics, outbreaks, 
VerDate Sep 11 2014 
01:48 Jun 12, 2024
Jkt 049200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6300
E:\BILLS\HR1286.IH
HR1286
kjohnson on DSK7ZCZBW3PROD with $$_JOB
•HRES 1286 IH 
and other health emergencies, while preserving the health 
of vaccine markets globally; 
Whereas Gavi is collaborating with the Global Polio Eradi-
cation Initiative on the final push to end polio, and ex-
panding the integration of the inactivated polio vaccine 
into routine immunization programs; 
Whereas Gavi has made significant progress in supporting 
the development and stockpiling of effective vaccines to 
combat cholera, measles, meningococcal, yellow fever, and 
Ebola, which could also protect Americans in the event 
of an outbreak on United States soil; 
Whereas malaria is one of most long-standing and deadliest 
diseases in Africa, and in 2022, malaria killed an esti-
mated 580,000 children in Africa, 78 percent of whom 
were children under five; 
Whereas Gavi has begun deliveries of new malaria vaccines 
and will expand the program to dozens of countries as 
vaccine supply becomes available; 
Whereas Gavi recently allocated 18,000,000 doses of the ma-
laria vaccine RTS,S in 2023 and 2024, the World Health 
Organization estimates that at least 40,000,000 to 
60,000,000 doses will be needed annually by 2026 and 
80,000,000 to 100,000,000 doses will be needed by 2030; 
Whereas Gavi is supporting expanded procurement, access, 
and implementation of new malaria vaccine programs to 
help meet rising demand; 
Whereas data from malaria vaccine trials indicate that these 
vaccines can save one life for every 200 children vac-
cinated, with the potential for significantly impacting 
public health and saving tens of thousands of lives annu-
ally; 
VerDate Sep 11 2014 
01:48 Jun 12, 2024
Jkt 049200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6300
E:\BILLS\HR1286.IH
HR1286
kjohnson on DSK7ZCZBW3PROD with $$_JOB
•HRES 1286 IH 
Whereas Gavi supports the strengthening of health systems 
to ensure effective immunization and health services, in-
cluding through the provision of cold chain equipment 
that can also be effectively repurposed for emergency re-
sponse, as was demonstrated during the COVID–19 pan-
demic; 
Whereas, through COVAX, Gavi and global partners deliv-
ered nearly 2,000,000,000 doses of COVID–19 vaccines 
to 146 economies, and averted an estimated 2,700,000 
deaths in Advance Market Commitment lower-income 
participating economies; 
Whereas Gavi is providing additional vaccine support to ad-
dress health service interruptions that occurred during 
the COVID–19 pandemic and contributed to the largest 
backslide in routine childhood immunization in 30 years, 
and is also focusing on the 14,000,000 ‘‘zero-dose’’ chil-
dren in Gavi-supported countries who had not received a 
single vaccine; 
Whereas vaccines programs are widely regarded as high-im-
pact, evidence-based interventions and are among the 
most efficient, cost-effective, and successful health initia-
tives in history, returning over $50 in health and eco-
nomic savings for every $1 invested in Gavi-supported 
countries; 
Whereas the prevention of infectious disease through immuni-
zation in Gavi-eligible countries provides protection and 
health security in the United States by reducing the prev-
alence of infectious diseases and stemming outbreaks at 
their source; 
Whereas United States investment in Gavi complements and 
enhances the effectiveness of other United States invest-
VerDate Sep 11 2014 
01:48 Jun 12, 2024
Jkt 049200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6300
E:\BILLS\HR1286.IH
HR1286
kjohnson on DSK7ZCZBW3PROD with $$_JOB
•HRES 1286 IH 
ments in global health, particularly in maternal and child 
health and nutrition; 
Whereas Gavi is committed to working with partners, includ-
ing United States bilateral programs administrated by 
the United States Agency for International Development 
(‘‘USAID’’) and the Centers for Disease Control and 
Prevention (‘‘CDC’’), to ensure children in developing na-
tions have access to lifesaving vaccines and immuniza-
tions; 
Whereas Gavi’s next strategic cycle will cover the strategic 
period of 2026 to 2030, which will include the expansion 
of Gavi’s malaria program; 
Whereas the launches of the Gavi’s Investment Opportunity 
for 2026 through 2030 and AVMA will be held in June 
2024 and co-hosted by the Government of France, Afri-
can Union, and Africa CDC to obtain funding commit-
ments; 
Whereas the United States has consistently supported the 
goal of saving lives by contributing annually to Gavi to 
meet its projected replenishment and program goals; 
Whereas with this support and support from other donors, 
Gavi will have contributed $220,500,000,000 in economic 
benefits in Gavi countries as of 2022, with each $1 in-
vested yielding $54 return on investment; and 
Whereas an increased commitment from the United States 
remains necessary to ensure predictability and stability to 
the vaccine market, to enable strong global health secu-
rity efforts, spur confidence in Gavi-eligible countries, 
and encourage continued innovative vaccine-related ap-
proaches: Now, therefore, be it 
Resolved, That the House of Representatives— 
VerDate Sep 11 2014 
01:48 Jun 12, 2024
Jkt 049200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\HR1286.IH
HR1286
kjohnson on DSK7ZCZBW3PROD with $$_JOB
•HRES 1286 IH 
(1) affirms the continued support of the United 
States Government for the purchase of vaccines for 
low-income countries through Gavi as a cost-effec-
tive, efficient means to reduce mortality and as a 
critical component of meeting the United States goal 
to end preventable child and maternal deaths; 
(2) supports the principles and goals of Gavi 
to— 
(A) introduce and scale up new and rou-
tine immunizations in low-income countries; 
(B) improve sustainability of immunization 
programs; 
(C) ensure healthy markets for vaccines 
and related products; and 
(D) strengthen health systems to increase 
equity in immunization; 
(3) recognizes that United States Government 
support for Gavi is a critical component to ensuring 
health security in the United States; 
(4) encourages the continued use of USAID 
maternal and child health and CDC global immuni-
zation resources to strengthen local public health ca-
pacity to introduce and sustain new and underuti-
lized vaccines supported by Gavi through routine im-
munization systems; 
VerDate Sep 11 2014 
01:48 Jun 12, 2024
Jkt 049200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\HR1286.IH
HR1286
kjohnson on DSK7ZCZBW3PROD with $$_JOB
•HRES 1286 IH 
(5) recognizes the need for multiyear pledges 
from the United States to allow Gavi to maximize its 
impact to provide lifesaving vaccines and to leverage 
contributions from other countries and donors; and 
(6) encourages continued increased commitment 
and investment by the United States Government to 
Gavi in the 2026 to 2030 strategic period in order 
to ensure that lives are protected and saved through 
access to vaccines and immunizations. 
Æ 
VerDate Sep 11 2014 
01:48 Jun 12, 2024
Jkt 049200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6301
E:\BILLS\HR1286.IH
HR1286
kjohnson on DSK7ZCZBW3PROD with $$_JOB